Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

書誌詳細
主要な著者:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
フォーマット:	Journal article
言語:	English
出版事項:	Wiley 2017

類似資料

Telomere length is a critical determinant for survival in multiple myeloma
著者:: Hyatt, S, 等
出版事項: (2017)

Maintenance of telomere length in AML
著者:: Peter M. Lansdorp
出版事項: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
著者:: Nadia El Menshawy, 等
出版事項: (2020-07-01)

Inherited predisposition to MDS/AML
著者:: Ana Rio Machin, 等
出版事項: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
著者:: Hamidollah Ghaffari, 等
出版事項: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
著者:: Hamidollah Ghaffari, 等
出版事項: (2009-06-01)

T cell memory revisited using single telomere length analysis
著者:: Laureline Roger, 等
出版事項: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
著者:: Barbara De Moerloose
出版事項: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
著者:: Theilgaard-Mönch, K, 等
出版事項: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
著者:: Jensen O, 等
出版事項: (2022-02-01)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
著者:: Olga K. Weinberg, 等
出版事項: (2023-08-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
著者:: Hoyle, C, 等
出版事項: (1989)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
著者:: Goh, Chermaine Yu Zhen
出版事項: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
著者:: Joanna E. Zawacka
出版事項: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
著者:: V. Sheth, 等
出版事項: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
著者:: A. G. Lema Fernandez, 等
出版事項: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
著者:: A Amaro, 等
出版事項: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
著者:: Petra Bašová, 等
出版事項: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
著者:: Udit Bhaskar Bhatnagar, 等
出版事項: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
著者:: Azra Raza, 等
出版事項: (2020-01-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
著者:: Christoforos K. Vaxevanis, 等
出版事項: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
著者:: YE Xiangjun, LU Xingguo
出版事項: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
著者:: V. Van Oorschot, 等
出版事項: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
著者:: Hongjiao Li, 等
出版事項: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
著者:: Lixian Chang, 等
出版事項: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
著者:: Guancui Yang, 等
出版事項: (2022-10-01)

Telomere length in myelodysplastic syndromes.
著者:: Boultwood, J, 等
出版事項: (1997)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
著者:: Barreyro, L, 等
出版事項: (2012)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
著者:: Anson Snow, 等
出版事項: (2022-07-01)

TELOMERE LENGTH AND ATHEROSCLEROSIS
著者:: O. M. Drapkina, 等
出版事項: (2016-09-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
著者:: Zuzana Tothova, 等
出版事項: (2021-02-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
著者:: T. Ueda, 等
出版事項: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
著者:: A. Shastri, 等
出版事項: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
著者:: Sandra Huber, 等
出版事項: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
著者:: Laura Barreyro, 等
出版事項: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
著者:: Victoria V. Grunwald, 等
出版事項: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
著者:: Amer M. Zeidan, 等
出版事項: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
著者:: Tahsin Anwar, 等
出版事項: (2023-12-01)

Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
著者:: Peter Vandenberghe, 等
出版事項: (2011-06-01)

Telomere length in myelodysplastic syndromes.
著者:: Boultwood, J, 等
出版事項: (1995)